Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This oral herbal combination preparation, consisting of pumpkin seed oil (*Cucurbita pepo*), Rhois bark dry extract (*Rhois aromatica*), and hop strobile dry extract (*Humulus lupulus*), is used to treat symptoms of overactive bladder (OAB) in women. Developed by GSK Consumer Healthcare (now Haleon), the product is marketed under the brand name Granu Fink Femina in certain European markets. The mechanism of action is attributed to the combined effects of its botanical ingredients: pumpkin seed oil is believed to strengthen the pelvic floor and bladder muscles; Rhois bark (sumac) acts as an astringent to reduce urinary frequency; and hop strobiles provide calming effects on the bladder. It has been studied in Phase 4 clinical trials to confirm its efficacy in reducing micturition frequency and urgency.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pumpkin seed oil + rhois bark dry extract + hop strobile dry extract.